Rock Springs Capital Management’s Fate Therapeutics FATE Stock Holding History

Rock Springs Capital Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-612,215	Closed	-$1.3M	–	109
2023 Q3	$1.3M	Hold	612,215	–	–	0.03%	105
2023 Q2	$2.91M	Hold	612,215	–	–	0.07%	98
2023 Q1	$3.49M	Buy	612,215 +502,215	+457%	+$3.03M	0.08%	97
2022 Q4	$1.11M	Hold	110,000	–	–	0.03%	111
2022 Q3	$2.46M	Hold	110,000	–	–	0.06%	110
2022 Q2	$2.73M	Hold	110,000	–	–	0.08%	109
2022 Q1	$4.26M	Hold	110,000	–	–	0.11%	107
2021 Q4	$6.44M	Hold	110,000	–	–	0.15%	110
2021 Q3	$6.52M	Buy	110,000 +40,000	+57%	+$3.14M	0.14%	122
2021 Q2	$6.08M	Hold	70,000	–	–	0.12%	133
2021 Q1	$5.77M	Buy	+70,000	New	+$6.71M	0.13%	128

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Rock Springs Capital Management's FATE Position: Q4 2023 in Review

Rock Springs Capital Management sold out of Fate Therapeutics (FATE) in Q4 2023, closing a stake of 612,215 shares — an estimated $1.3M sold.

Rock Springs Capital Management first reported a position in FATE in Q1 2021 and held it in 11 quarters. The position peaked at $6.52M in Q3 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

Rock Springs Capital Management reported no remaining Fate Therapeutics position as of Q4 2023 after selling out during the quarter.
Rock Springs Capital Management sold 612,215 Fate Therapeutics shares in Q4 2023, an estimated $1.3M.
Rock Springs Capital Management first reported a position in Fate Therapeutics in Q1 2021 and held it in 11 quarters.
Rock Springs Capital Management's Fate Therapeutics position peaked at $6.52M in Q3 2021.
159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.